Department of Orthopedics and Traumatology, Shenzhen Longhua District Central Hospital, Shenzhen 518110, China.
Department of Health Management, Shenzhen Longhua District Central Hospital, Shenzhen 518110, China.
Math Biosci Eng. 2022 Mar 25;19(6):5361-5379. doi: 10.3934/mbe.2022251.
PTPRD plays an indispensable role in the occurrence of multiple tumors. However, pan-cancer analysis is unavailable. The purpose of this research was to preliminarily study its prognostic landscape across various tumors and investigate its relationship with immunotherapy. We exhibited the expression profile, survival analysis, and genomic alterations of PTPRD based on the TIMER, GEPIA, UALCAN, PrognoScan and cBioPortal database. The frequency of PTPRD mutation and its correlation with response to immunotherapy were evaluated using the cBioPortal database. The relationship between PTPRD and immune-cell infiltration was analyzed by the TIMER and TISIDB databases. A protein interaction network was constructed by the STRING database. GO and KEGG enrichment analysis was executed by the Metascape database. A correlation between PTPRD expression and prognosis was found in various cancers. Aberrant PTPRD expression was closely related to immune infiltration. In non-small cell lung cancer and melanoma, patients with PTPRD mutations had better overall survival with immune checkpoint inhibitors, and these patients had higher TMB scores. PTPRD mutation was involved in numerous biological processes, including immunological signaling pathways. A PTPRD protein interaction network was constructed, and genes that interacted with PTPRD were identified. Functional enrichment analysis demonstrated that a variety of GO biological processes and KEGG pathways associated with PTPRD were involved in the therapeutic mechanisms. These results revealed that PTPRD might function as a biomarker for prognosis and immune infiltration in cancers, throwing new light on cancer therapeutics.
PTPRD 在多种肿瘤的发生中起着不可或缺的作用。然而，目前缺乏泛癌症分析。本研究旨在初步研究其在各种肿瘤中的预后图谱，并探讨其与免疫治疗的关系。我们根据 TIMER、GEPIA、UALCAN、PrognoScan 和 cBioPortal 数据库展示了 PTPRD 的表达谱、生存分析和基因组改变。使用 cBioPortal 数据库评估了 PTPRD 突变的频率及其与免疫治疗反应的相关性。通过 TIMER 和 TISIDB 数据库分析了 PTPRD 与免疫细胞浸润的关系。通过 STRING 数据库构建了蛋白质相互作用网络。通过 Metascape 数据库进行了 GO 和 KEGG 富集分析。在各种癌症中发现了 PTPRD 表达与预后之间的相关性。异常的 PTPRD 表达与免疫浸润密切相关。在非小细胞肺癌和黑色素瘤中，携带 PTPRD 突变的患者接受免疫检查点抑制剂治疗后总生存期更好，且这些患者的 TMB 评分更高。PTPRD 突变涉及多种生物学过程，包括免疫信号通路。构建了 PTPRD 蛋白相互作用网络，并鉴定了与 PTPRD 相互作用的基因。功能富集分析表明，与 PTPRD 相关的多种 GO 生物学过程和 KEGG 途径参与了治疗机制。这些结果表明，PTPRD 可能作为癌症预后和免疫浸润的生物标志物，为癌症治疗提供了新的思路。
